174 related articles for article (PubMed ID: 11876689)
1. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.
Tripathi D; Therapondos G; Lui HF; Stanley AJ; Hayes PC
Aliment Pharmacol Ther; 2002 Mar; 16(3):373-80. PubMed ID: 11876689
[TBL] [Abstract][Full Text] [Related]
2. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis.
Forrest EH; Bouchier IA; Hayes PC
J Hepatol; 1996 Dec; 25(6):909-15. PubMed ID: 9007720
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.
Stanley AJ; Therapondos G; Helmy A; Hayes PC
J Hepatol; 1999 Mar; 30(3):479-84. PubMed ID: 10190732
[TBL] [Abstract][Full Text] [Related]
4. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
5. The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis.
Fierbinteanu-Braticevici C; Udeanu M; Dragomir P; Andronescu D
Rom J Intern Med; 2003; 41(3):247-54. PubMed ID: 15526508
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Sinagra E; Perricone G; D'Amico M; Tinè F; D'Amico G
Aliment Pharmacol Ther; 2014 Mar; 39(6):557-68. PubMed ID: 24461301
[TBL] [Abstract][Full Text] [Related]
7. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
8. The role of carvedilol in the management of portal hypertension.
Tripathi D; Hayes PC
Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):905-11. PubMed ID: 20093937
[TBL] [Abstract][Full Text] [Related]
9. After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis?
Wani ZA; Baht RA; Bhadoria AS; Maiwall R; Majeed Y; Khan AA; Zargar SA; Shah MA; Khan KM
Saudi J Gastroenterol; 2015; 21(5):278-83. PubMed ID: 26458853
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Bañares R; Moitinho E; Matilla A; García-Pagán JC; Lampreave JL; Piera C; Abraldes JG; De Diego A; Albillos A; Bosch J
Hepatology; 2002 Dec; 36(6):1367-73. PubMed ID: 12447861
[TBL] [Abstract][Full Text] [Related]
11. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Hobolth L; Bendtsen F; Hansen EF; Møller S
Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
[TBL] [Abstract][Full Text] [Related]
12. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
Sekiyama T; Komeichi H; Nagano T; Ohsuga M; Terada H; Katsuta Y; Satomura K; Aramaki T
Arzneimittelforschung; 1997 Apr; 47(4):353-5. PubMed ID: 9150854
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol or propranolol in portal hypertension? A randomized comparison.
Hobolth L; Møller S; Grønbæk H; Roelsgaard K; Bendtsen F; Feldager Hansen E
Scand J Gastroenterol; 2012 Apr; 47(4):467-74. PubMed ID: 22401315
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Li T; Ke W; Sun P; Chen X; Belgaumkar A; Huang Y; Xian W; Li J; Zheng Q
BMJ Open; 2016 May; 6(5):e010902. PubMed ID: 27147389
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of carvedilol for the treatment of portal hypertension.
Hemstreet BA
Pharmacotherapy; 2004 Jan; 24(1):94-104. PubMed ID: 14740791
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Reiberger T; Ulbrich G; Ferlitsch A; Payer BA; Schwabl P; Pinter M; Heinisch BB; Trauner M; Kramer L; Peck-Radosavljevic M;
Gut; 2013 Nov; 62(11):1634-41. PubMed ID: 23250049
[TBL] [Abstract][Full Text] [Related]
17. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis.
Aguilar-Olivos N; Motola-Kuba M; Candia R; Arrese M; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
Ann Hepatol; 2014; 13(4):420-8. PubMed ID: 24927613
[TBL] [Abstract][Full Text] [Related]
19. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
De BK; Das D; Sen S; Biswas PK; Mandal SK; Majumdar D; Maity AK
J Gastroenterol Hepatol; 2002 Feb; 17(2):183-9. PubMed ID: 11966949
[TBL] [Abstract][Full Text] [Related]
20. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
Silkauskaitė V; Kupčinskas J; Pranculis A; Jonaitis L; Petrenkienė V; Kupčinskas L
Medicina (Kaunas); 2013; 49(11):467-73. PubMed ID: 24823927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
